Scarica l'app Stockscreener
8.17
0.74%
0.06
Dopo l'orario di chiusura:
8.17
Precedente Chiudi:
$8.11
Aprire:
$8.13
Volume 24 ore:
33,561
Relative Volume:
0.39
Capitalizzazione di mercato:
$212.44M
Reddito:
$26.00M
Utile/perdita netta:
$-219.71M
Rapporto P/E:
-0.1641
EPS:
-49.8
Flusso di cassa netto:
$-51.37M
1 W Prestazione:
-10.81%
1M Prestazione:
-20.06%
6M Prestazione:
-31.92%
1 anno Prestazione:
-58.74%
Intervallo 1D:
$8.0901
$8.38
Intervallo di 1 settimana:
$7.75
$9.49
Portata 52W:
$7.75
$26.50
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Nome
Cartesian Therapeutics Inc
Settore
Industria
Telefono
301-348-8698
Indirizzo
7495 NEW HORIZON WAY, FREDERICK
Confronta RNAC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
8.17 | 210.88M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-09 | Iniziato | Wedbush | Outperform |
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-08-06 | Iniziato | TD Cowen | Buy |
| 2024-07-02 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Iniziato | Oppenheimer | Outperform |
| 2024-05-24 | Iniziato | Mizuho | Buy |
| 2024-04-23 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-23 | Iniziato | Leerink Partners | Outperform |
| 2023-08-18 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Reiterato | Needham | Buy |
| 2022-06-06 | Iniziato | SVB Leerink | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-01-26 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-10-01 | Downgrade | Mizuho | Buy → Neutral |
| 2020-10-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Downgrade | Stifel | Buy → Hold |
| 2020-04-28 | Iniziato | H.C. Wainwright | Buy |
| 2020-01-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Iniziato | William Blair | Outperform |
| 2018-06-27 | Iniziato | Janney | Buy |
| 2017-03-30 | Reiterato | UBS | Buy |
Mostra tutto
Cartesian Therapeutics Inc Borsa (RNAC) Ultime notizie
Key metrics from Cartesian Therapeutics Inc.’s quarterly dataEarnings Overview Report & Risk Controlled Daily Trade Plans - newser.com
Is Cartesian Therapeutics Inc. a candidate for recovery playEarnings Trend Report & Verified Entry Point Signals - newser.com
What makes Cartesian Therapeutics Inc. (1S70) stock appealing to growth investors2025 Year in Review & Daily Momentum Trading Reports - newser.com
Will Cartesian Therapeutics Inc. price bounce be sustainableVolume Spike & Daily Growth Stock Tips - newser.com
How Cartesian Therapeutics Inc. (1S70) stock expands through international marketsJuly 2025 PostEarnings & Risk Controlled Stock Pick Alerts - newser.com
How to read the order book for Cartesian Therapeutics Inc.2025 Market WrapUp & Community Trade Idea Sharing - newser.com
Will Cartesian Therapeutics Inc. stock outperform tech sector in 2025Entry Point & High Conviction Buy Zone Picks - newser.com
Working capital per share of Cartesian Therapeutics, Inc. – FWB:1S70 - TradingView
Is Cartesian Therapeutics Inc. stock near bottom after declineWeekly Risk Summary & Short-Term Swing Trade Alerts - newser.com
Combining price and volume data for Cartesian Therapeutics Inc.Quarterly Earnings Summary & Long-Term Capital Growth Ideas - newser.com
Is Cartesian Therapeutics Inc. stock supported by strong fundamentalsJuly 2025 Setups & Daily Volume Surge Trade Alerts - newser.com
Will Cartesian Therapeutics Inc. (1S70) stock gain from green policiesBear Alert & Verified Trade Idea Suggestions - newser.com
How Cartesian Therapeutics Inc. stock performs during Fed tightening cycles2025 Market Trends & Technical Buy Zone Confirmation - newser.com
Is a relief rally coming for Cartesian Therapeutics Inc. holdersOil Prices & Reliable Entry Point Trade Alerts - newser.com
Cartesian Therapeutics, Inc. (RNAC) Analyst insights, Price targets and Recommendations - Yahoo! Finance Singapore
Cartesian Therapeutics (RNAC) Expected to Announce Earnings on Thursday - MarketBeat
Cartesian Therapeutics Announces Leadership Changes - The Globe and Mail
Is Cartesian Therapeutics Inc. trending in predictive chart models2025 Price Momentum & Fast Momentum Entry Tips - newser.com
Ranking Cartesian Therapeutics Inc. among high performing stocks via tools2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com
What indicators show strength in Cartesian Therapeutics Inc.Portfolio Risk Summary & Daily Volume Surge Signals - newser.com
Cartesian Therapeutics Appoints Carsten Brunn, Ph.D., as Board Chairman - citybiz
Cartesian Therapeutics, Inc. Announces Board and Committee Changes, Effective from October 29, 2025 - MarketScreener
Cartesian Therapeutics (RNAC) Grants Stock Options to New Employ - GuruFocus
Cartesian Therapeutics Advances SLE Treatment with Descartes-08 Study - MSN
Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times
Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors - The Manila Times
Cartesian Therapeutics Announces Board Changes - TradingView
RNAC names Carsten Brunn Board Chair; adds Lead Independent Director - Stock Titan
Cartesian Therapeutics (NASDAQ: RNAC) grants options at $8.85 and $8.20 inducement - Stock Titan
Cartesian Therapeutics (NASDAQ: RNAC) appoints CEO Carsten Brunn as chairman - Stock Titan
Is Cartesian Therapeutics Inc. building a consolidation baseWeekly Volume Report & Smart Money Movement Alerts - newser.com
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Cartesian Therapeutics Inc Azioni (RNAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):